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Abstract: Ageing and skin exposure to UV radiation induces production and activation of matrix met-
alloproteinases (MMPs) and human neutrophil elastase (HNE). These enzymes are known to break 
down the extracellular matrix (ECM) which leads to wrinkle formation. Here, we demonstrated the po-
tential of a solid-in-oil nanodispersion containing a competitive inhibitor peptide of HNE mixed with 
hyaluronic acid (HA), displaying 158 nm of mean diameter, to protect the skin against the ageing effects. Western blot 
analysis demonstrated that activation of MMP-1 in fibroblasts by HNE treatment is inhibited by the solid-in-oil nanodis-
persion containing the peptide and HA. The results clearly demonstrate that solid-in-oil nanodispersion containing the 
HNE inhibitor peptide is a promising strategy for anti-ageing effects. This effect can be seen particularly by ECM regula-
tion by affecting fibroblasts. The formulation also enhances the formation of thicker bundles of actin filaments.  
Keywords: Protease, inhibitory peptide, proteolysis, immunoassay, diffusion, nanodispersion.  
INTRODUCTION 
 The ageing effects of exposure to sunlight on human skin 
have been largely recognized. The alterations provoked in 
skin are mostly caused by ultraviolet spectrum (wavelengths 
between 240-400 nm). Extended and continuum exposure to 
ultraviolet radiation (UV) will accelerate skin aging, typi-
cally designated as photoaging [1]. The severity of pho-
toaging depends on cumulative sun exposure, occupation and 
life-style [2]. It is characterized by the appearance of wrin-
kles, laxity, roughness, dryness and irregular pigmentation 
[3]. It has also been reported that photoaging is associated 
with the increased of collagenase synthesis resulting in a 
thinned epidermis, dysplasia of keratinocyte and collagen 
degradation in the layers of the dermis. The decrement of 
collagen production is related with the loses of elasticity, and 
the breakdown of fibroblasts are related with the wrinkles 
formation [4].   
 The extracellular matrix (ECM) is composed by the most 
common components secreted by fibroblasts like viscous 
proteoglycans, fibronectin and collagen fibers [5]. Elastase 
type-proteases are shown to actively degrade fibronectin [6]. 
Elastase is the major product from activated skin-infiltrating 
neutrophils that expand the inflammatory response initiated 
by UV radiation. Biologically, the breakdown of elastin and 
collagen as well as the augment of elastase activity promotes 
the decline of elasticity and the subsequent formation of the  
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stretchmarks and wrinkles [7]. Human neutrophil elastase 
(HNE) is an enzyme capable of degrading almost all ECM 
proteins as well as a variety of key plasma proteins [8].  
 Matrix metalloproteinase (MMPs) is a family of extracel-
lular zinc-containing endopeptidases [5a, 5c, 5d, 9]. The 
ECM is composed by their substrates which are different 
types of collagen, matrix glycoproteins and proteoglycans. 
MMPs are grouped through substrate specificities as mem-
brane-type MMPs, stromelysins, gelatinases and colla-
genases. MMPs strongly contribute to the ECM damage and 
the decreased procollagen synthesis leading to the formation 
of photoaged skin [10]. In addition, the damage of the der-
mal ECM is histologically characterized by the accumulation 
of disintegrated abnormal elastic fibers in the upper dermis 
[11]. The identification of products capable to inhibit MMPs 
is emerging in pharmaceutical area for the prevention or ag-
ing treatment of skin [12].  
 The harmful effects on skin from UVs radiation can be 
direct and indirectly formed. After chronic UV irradiation, 
neutrophils infiltrate into the skin and release HNE, which 
participates both direct and indirectly in the formation of 
wrinkles. HNE is indirectly involved in ECM deterioration 
by the activation of matrix MMPs and through direct prote-
olytic action [13]. Therefore, the inhibition of elastase activ-
ity and the subsequent inhibition of active MMPs might be 
an effective method to protect and/or prevent skin aging ef-
fects.  
 Herein, we used a methodology of solid-in-oil nanodis-
persion containing a HNE inhibitory peptide, which could be 
potentially applied for anti-ageing effects. We described re-
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cently a solid-in-oil nanodispersion technique for transder-
mally delivery large hydrophilic macromolecules like bovine 
serum albumin (BSA) and hyaluronic acid [14]. Here, we 
access the anti-ageing effects of a peptide after perfusion 
through the skin. The strongest HNE inhibitory peptide was 
chosen based on the HNE inhibitory activity of two peptides 
(with the Bowman–Birk reactive-site loop motive) studied 
for wound healing applications [15]. Western blot analyses 
were performed to demonstrate its capacity to prevent the 
activation of MMP1 by HNE in vitro. In addition, actin fila-
ments of the cytoskeleton of human skin fibroblasts were 
evaluated by staining with phalloidin. This solid-in-oil nano-
dispersion is a promising strategy for the development of a 
new cosmetic product for ECM homeostasis, preventing its 
degradation by inhibition of MMP-1 and dermal fibroblasts 
increased cytoskeleton density.  
MATERIALS AND METHODS 
Materials 
 The peptide ((MGWCTASVPPQCY(GA)7, 2339.62 
g/mol) was synthetized by JPT Peptide Tecnologies GmbH 
(Germany). Sucrose ester (SE) was purchased from Sisterna 
(Netherland). Hyaluronic acid (20Mw50 kDa) was kindly 
provided from Soliance (France). Regarding histological 
preparations, the Immuno-Mount compound was acquired 
from Fisher Healthcare (UK) and the cryoprotectant com-
pound was purchased from Sakura (Netherland). The SDS-
PAGE and Western Blotting solutions were purchased to 
BioRad (Portugal). All other chemical and biochemical rea-
gents were analytical grade and purchased from Sigma-
Aldrich (USA).  
 The percutaneous studies were accomplished by pig skin 
kindly provided by the slaughterhouse Matadouro Central de 
Entre Douro e Minho (Portugal). The cell line (hTERT) 
BJ5ta, an immortalized human dermal fibroblasts, was ac-
quired by European Collection of Cells Culture (ECACC) 
and cultured following the recommendations of ATCC. The 
ASF-2 cells (human skin fibroblasts) were isolated and 
maintained as described by Cristovão et al. [16]. The human 
keratinocyte cell line, NCTC 2544, was obtained from Insti-
tuto Zooprofilattico Sperimentale della Lombardia e 
dell’Emilia Romagna (Brescia, Italy) and maintained accord-
ing to the supplier instructions.  
Assessment of Indirect Inhibitory Activity of the Peptide 
on MMP-1 Proteolytic Activation In Vitro by Western 
Blot 
 To determine the ability of the formulation to prevent 
pro-MMP1 activation, the chosen concentration was based 
on the lowest dilution without cytotoxicity. The concentra-
tion used was 2% (v/v) of peptide/HA solid-in-oil nanodis-
persion, corresponding to 10 μg of peptide for each mL of 
culture medium. The BJ5ta fibroblasts were grown in 
DMEM (Dulbecco’s Modified Eagle’s Medium) with 10% 
FBS, seeded at 155000 cells in a 12-well cell plates. The 
replacement of culture medium (with DMEM) was per-
formed after 24 hours post-seeding followed by the addition 
of 1 ng/mL of TNF- for 48h, to induce the metalloprotein-
ase proMMP-1. Then, for the proteolytic activation of the 
proMMP-1, HNE was added 24h before the end of the 48h 
incubation period (20 mU of HNE, Sigma). Thirty minutes 
after adding the HNE, the inhibitors, the same amount of free 
peptide and formulated peptide, were added to the wells. 
When the experiment ended, the culture media it was taken 
and concentrated by lyophilization.  
 After rehydration, the total amount of protein was deter-
mined by DC Assay (colorimetric assay for protein concen-
tration, BioRad). The samples were diluted to normalize the 
values to the least concentrated sample (around 0.72 g/L) 
and the maximum volume was loaded (20 μL) and the cul-
ture media samples were analyzed by 12% SDS-PAGE. The 
gel was then transferred onto a polyvinylidine difluoride 
(PVDF) membrane (BioRad). The membrane was blocked 
with blocking buffer for one hour and then it was incubated 
with purified antibody (polyclonal rabbit) against the N-
terminus of human MMP-1 (Sc-8834-R, Santa Cruz Bio-
technology, Germany) for 2 h. After that, the membrane was 
washed and was proceeded to its incubation with HRP-
labeled goat anti-rabbit IgG (sc-2004, Santa Cruz Biotech-
nology, Germany) with 1 L of the HRP conjugate (Preci-
sion protein Strep Tactin- BioRad, Portugal) for one hour. 
The membrane was rinsed and then incubated using the mix 
substrate kit components (ECL Clarity, BioRad) in a 1:1 
ratio for 5 min. Bands detected on the PVDF membrane were 
analyzed by chemiluminescence (Chemidoc XRS + System, 
BioRad, Portugal).  
Effect of the Formulated HA on the Cytoskeleton of Fi-
broblasts by Fluorescent Phalloidin 
 Two types of fibroblasts (immortalized fibroblasts: BJ-
5ta cell line and primary human fibroblasts: ASF-2) were 
cultured for 24 hours at low confluence (50000 cells per 
well). The cells were grown on sterile coverslips in the bot-
tom of each 24-well cell plates of polystyrene, in the pres-
ence or absence of hyaluronic acid, either formulated or in 
the free form. After washing three times with PBS at 37ºC, 
cells were fixed at room temperature using 3.7% of formal-
dehyde in PBS during 10 minutes. Then, cells were washed 
two times with PBS. Thereafter, cells were permeabilized in 
0.1% of Triton X-100 (in PBS) for 3-5 minutes and then 
were washed two times with PBS. The cytoskeleton was 
stained with 5 U/mL phalloidin incubated for 20 minutes at 
room temperature in the dark. Once washed with PBS, the 
coverslip was removed from the well with forceps and the 
excess of PBS was allowed to drip off. Coverslips were 
mounted (cells facing down) onto the slide containing one 
drop of anti-fade mounting medium (Vectashield® Mount-
ing Media). This medium is glycerol-based and it contains 
the counterstain 4’, 6-diamidino-2-phenylindole (DAPI) that, 
when bound to DNA produces a blue fluorescence. Slides 
were analyzed under Olympus IX70 inverted epi-
fluorescence microscope, using Cell^F Imaging Solutions 
GmbH software (v3.4). The cell morphology and cytoskele-
ton effect (actin filaments density) were analyzed. 
Percutaneous Studies: Qualitative and Quantitative 
Penetration Profile 
 The skin specimens were prepared by carefully removing 
the subcutaneous fat, and then immediately used for penetra-
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tion studies. In vitro penetration studies were performed us-
ing a Franz diffusion cell (PermeGear, USA). The skin sam-
ples were sandwiched between the upper (donor chamber) 
and bottom (receptor chamber) compartment. In the donor 
chamber was placed 300 L of the formulation and in the 
receptor chamber was placed 5 mL of PBS (phosphate-
buffered saline, 0.01 M, pH 7.4) which was maintained at 
37ºC, so the skin sample reaches 32±1 ºC, the physiological 
skin temperature, in a circulating water bath (Thermo Scien-
tific SC 100, Germany). An aliquot (150 l) of the receptor 
compartment was collected at predetermined time intervals, 
0, 2, 4, 6, 8, 24, 48 and 72 hours. Fresh buffer was replaced 
for each volume removed. The percutaneous penetration was 
assessed using the Lowry assay to quantify the protein con-
centration and monitoring the absorbance at 185 nm to detect 
the HA concentration for each sample removed. Controls 
samples, without the presence of peptide and HA, were per-
formed. 
 The qualitative permeation profile of peptide/HA solid-
in-oil nanodispersion through the skin was performed by 
confocal laser scanning microscopy. In order to profile the 
permeation, a solid-in-oil nanodispersion was prepared with 
the Fluorescein Isocyanate (FITC)- labelled peptide and the 
Rhodamine Isocyanate (RITC)- labelled HA. After 72 hours, 
the removal pig skin specimens from Franz cells were per-
formed. Then, these skin samples were incorporated into 
OCT and frozen at -80ºC. The frozen skin samples were sec-
tioned with a cryostat into 20 m slices. The permeation of 
the fluorescent compounds was assessed by confocal laser 
microscopy (Leica TCS SPE, Germany). All optical sections 
were recorded with the same settings. The slides of FITC- 
labelled peptide which fluorescent emission signal is repre-
sented by a green colour. RITC labelled HA which fluores-
cent emission signal is represented by a red colour.  
Molecular Dynamics Simulation 
 For the simulations we used the software package 
GROMACS [17] (version 4.6.2). The force filed used was 
Martini [18]. The size of the simulation box was determined 
according to the minimum image convention (according to a 
cut-off of 1.2 nm). LINCS [19] was used to constrain the 
bonds lengths and the non-bonded interactions were calcu-
lated using a twin-range method (short range cut-off = 0.9 
nm, long range cut-off = 1.2 nm). Neighbour search was 
updated every ten steps and carried out up to 1.2 nm. The 
integration time step used was 5 fs, and for the electrostatics 
interactions we considered a reaction field correction using a 
dielectric constant of 15. Berendsen barostat [20] and Ber-
endsen thermostat [20] were used. Reference pressure of 1 
bar, 3.0 ps of relaxation time and isothermal compressibility 
of 3.010-5 bar-1. Temperature was set at 300 K. Separated 
heat baths (coupling constants of 0.30 ps) were considered 
for each component of the system. Two replica simulations 
(320 ns in length) were carried out. Different initial veloci-
ties were taken from a Maxwell-Boltzman distribution at 300 
K. The lipid membrane and the proteic nanoemulsion were 
built using the same approach described in our previous 
work [14b].   
 
RESULTS 
In Vitro Inhibitory Activity of the Peptide/HA Nanofor-
mulation on Ageing-Associated Proteases by Western 
Blot 
 In vitro detection by western blot demonstrated a de-
creased level of active MMP-1 due to the HNE inhibition, 
where it was dependent on the availability of the peptide to 
the dermal fibroblasts (Fig. 1). The control formulation using 
BSA instead of the peptide was not able to inhibit HNE (data 
not shown).  
 Considering that cytokines can induce the production of 
MMPs by broblasts, we stimulated fibroblasts with TNF-. 
When fibroblasts were stimulated by adding to the medium 
the cytokine TNF-, the induction of proMMP-1 (Mw 54 
kDa) was observed after 48h (Fig.1: lane 2-5), compared to 
the basal levels secreted by fibroblasts without TNF- 
(Fig.1: lane 1). MMP-1 is secreted by fibroblasts in its inac-
tive form (proMMP-1) being activated when cleaved by 
HNE released by Neutrophil cells recruited after a stimuli 
like UV radiation [13]. Thus, we incubated the fibroblasts 
with 20 mU/mL HNE 24 hours after addition of TNF- 
(HNE concentration was non-toxic data not shown). After 30 
minutes of exposure to HNE, the inhibitors (free and formu-
lated peptide) were added to the medium. As shown in Fig.1, 
MMP-1 was not activated in the absence of HNE (lane 2), 
only being activated in the presence of HNE (lane 3-5: pep-
tides at 22/25 and 27 kDa).  
Assessment of Actin Cytoskeleton by Dermal Fibroblasts 
in Contact with Peptide/HA Nanoformulation 
 The assessment of actin cytoskeleton display vital impact 
in cell`s mechanical stability and the evaluation of actin 
fibers it is essential to demonstrate anti-ageing benefits. The 
effect of HA on the cytoskeleton of dermal fibroblasts was 
evaluated in two types of cells: immortalized human normal 
skin fibroblasts (BJ-5ta) and primary human fibroblasts 
(ASF-2). After exposing fibroblasts for 24 hours in presence 
or absence of HA in formulated and free form, the actin 
filaments density was analyzed through inverted epi-
fluorescent microscope. The images in Fig. 2 shows that the 
presence of HA contributes for a dense actin filament bun-
dles for both cell types.. This assessment was revealed by 
staining with fluorescently labelled phalloidin.  
Qualitative and Quantitative Percutaneous Profile 
 The perfusion of peptide/HA into the skin was success-
fully achieved using the S/O nanodispersion. Fig. 3 clearly 
demonstrates that the S/O nanodispersion of peptide/HA 
crosses the stratum corneum (SC) barrier spreading into epi-
dermis and dermis of the skin. The images reveal the effec-
tive permeation of the peptide labelled with FITC (green) 
and hyaluronic acid labeled with RITC (red) into the differ-
ent layers of pig skin.  
 The skin permeability of peptide/HA was also examined 
quantitatively (according to our preceding study) [14a]. Con-
sidering the cumulative amount of peptide and HA, the ef-
fective penetration of peptide/HA S/O nanodispersion 
through the skin was shown in Table 1.  
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Figure 1. Inhibition of active MMP-1 secreted by fibroblasts when cleaved by HNE was assayed by analysis of western blot. Lane 1 and 2: 0 
and 1 ng/mL of TNF-, respectively; Lane 3: 1 ng/mL of TNF- plus 20 mU/mL of HNE; Lane 4: 1 ng/mL of TNF- with 20 mU/mL of 
HNE plus free peptide and lane 5 equal to lane 4 but with peptide/HA solid-in-oil nanodispersion (SOND). In order to confirm the intensity of 
each band was quantified using integrated density by Image J software. 
 
(A) 
 
(B) 
 
 
Figure 2. Images of actin cytoskeleton of dermal fibroblasts (A) BJ-5ta immortalized fibroblasts and (B) ASF-2 normal human fibroblasts 
revealed by fluorescent phalloidin. Cells grown at different conditions: control, formulated HA into peptide/HA solid-in-oil nanodispersion 
(0.12 g/mL), free HA (0.12 g/mL) and positive control (free HA 1mg/mL), in the culture medium from 24 hours.  
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Figure 3. Confocal 2D images of pig skin crossed by peptide/HA solid-in-oil nanodispersion. Images of control sample, formulation non-
diluted (A), formulation at 2% (v/v) (B) and 0.5% (v/v) (C). Figure shows the phase contrast images, FITC pictures (green colour with maxi-
mum emission at 520 nm) emitting FITC-labelled peptide and RITC (red colour with maximum emission at 595nm) emitting RITC-labeled 
HA. The Merge pictures combine FITC and RITC signals.  
 
Table 1. Cumulative amount of peptide/HA solid-in-oil nano-
dispersion 2% (v/v) permeated after 0.5, 2, 8, 24 and 
48 hours through pig skin (surface area 0.785 cm
2
) 
maintained at 37ºC. Each value represents the mean 
cumulative amount for 3 experiments ± standard de-
viation.  
Time of permeation (hours) 
Cumulative amount  
(Qt) (g/cm2)
0.5 52.3 ± 3.9 
2 156.7 ± 4.2 
8 230.9 ± 5.4 
24 271.5 ± 4.5 
48 338.8 ± 3.9 
 
 Molecular dynamics simulations predicted and confirmed 
skin permeation of this formulation (Fig. 4). The image 
demonstrates that the peptide/HA S/O nanodispersion after 
300 ns is completely integrated into the top bilayer.  
 The nanodispersion formulation was fundamental to 
transdermally delivery hydrophilic components through the 
skin. The combination of the peptide and HA spread into the 
skin constitute a great strategy for possible cosmetics appli-
cations, especially related with anti-ageing (Fig. 5).  
DISCUSSION 
 In this paper, we access the anti-ageing effects of a pep-
tide after it perfusion through the skin. The peptide (competi-
tive inhibitor for HNE) was delivered across the skin using a 
solid-in-oil nanodispersion with HA. The production yield 
(calculated according other previous study [14a]) of the for-
mulation was around 78%. Previous studies performed by 
Vasconcelos et. al., 2011, demonstrated that this peptide is a 
competitive inhibitor for HNE [15]. This short peptide se-
quence has the potential to be incorporated in skin anti-
ageing formulations based on its capacity to inhibit ageing-
associated proteases (HNE and indirectly MMP-1) of ECM 
produced by dermal fibroblasts.  
 The skin ageing process is divided into two categories, 
intrinsic ageing and extrinsic ageing (known as photoaging) 
[21]. The first category is identified by dried, smooth, pallid 
and fine wrinkled skin aspect; the second category is identi-
fied by alterations of pigmentation and formation of wrin-
kles, typically in the face and neck as well as forearm which 
are the areas typically exposed to the sun [8]. Several evi-
dences established a strong correlation between the forma-
tion of wrinkles and the MMPS actions [22]. Researchers 
have been assuming that dermal connective tissue can suffer 
alterations in skin areas exposed to radiation from the sun 
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[13, 23]. It is believed that UVs radiation, particularly UVB, 
plays an important role in photoaging process and induces 
the expression of MMP-1 (interstitial collagenase of MMPs) 
in human dermal and epidermis layers [24].  
 Herein, in order to examine the inhibition of MMP-1 
secreted by fibroblasts from peptide/HA solid-in-oil nano-
dispersion, activation of MMP-1 in fibroblasts was required. 
The amount of TNF- and time for the MMP1 induction in 
BJ5ta was optimized and the peptide/HA nanodispersion was 
not able per si to induce MMP-1 induction (data not shown).  
 In Fig. 1 the results strongly indicate that the peptide is 
able to lower the amount of active MMP1 by inhibiting the 
proteolytic activity of HNE (lane 4 and 5). Protein bands did 
not show signal saturation. It is also worth of note that the 
free peptide presents a stronger inhibitory effect (lane 4) than 
the formulated peptide (lane 5) which demonstrate that when 
 
 
 
 
 
 
 
 
 
 
Figure 4. Representation of time evolution by computational dynamics simulation. The picture illustrates snapshots of the dynamics simula-
tions at 0 ns, 60 ns, 120 ns, 180 ns, 240 ns and 300 ns. The peptide is represented by green color, hyaluronic acid by red, Surfactant SE by 
orange and IPM by blue color.  
 
 
 
Figure 5. Schematic representation of the methodology used and biology effects of the peptide and HA after perfusion through the skin. 
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all formulation crosses the skin the peptide dissociates from 
the nanodispersion being completely free to act. Once MMP-
1 plays greater role in maintaining elasticity of the skin and it 
resilience, to prevent or inhibit MMP-1 action constitute a 
potential approach to reduce or prevent photoaging.  
 The data obtained from ex vivo permeation studies sup-
port the assumption that once this solid-in-oil nanodispersion 
penetrates the skin it has a strong tendency to dissociate due 
to various factors including the diffusion membrane material, 
skin conditions among others [14a]. Given that, once the 
peptide is disintegrated from the complex loses it spherical 
form becoming freely available to act into the skin. It is ex-
pected that this competitive HNE inhibitor peptide, MGWCT 
ASVPPQCYG(GA)7, lower the levels of active MMP-1 and 
consequently be able to reduce subsequent collagen break-
down thereby preventing skin ageing. It is well documented 
that MMP-1 triggers the collagen degradation which un-
winds the triple-helical collagen structure and break peptide 
bonds by hydrolysis [25]. After collagen degradation follow-
ing its conversion to denaturated form, gelatin, and its de-
generation by gelatinases [25]. Therefore, the inhibition of 
elastase and subsequently prevention or inhibition of active 
MMP-1 constitute pivotal role to reduce effects of skin age-
ing. Given that, these results suggest that the peptide/HA 
solid-in-oil nanodispersion could represent a valuable ap-
proach for the development of new cosmetic anti-ageing 
product.  
 Several outcomes in literature indicate that HA is a uni-
versal component of ECM and plays an important role in 
tissue hydration, cell function and ECM regulation [26]. Sig-
nificant histological features of photoaged skin include the 
ECM deformation and collagen reduction. These characteris-
tics lead to a loss of strength and elasticity of the skin. [27]. 
Once changes in mechanical properties could determine fea-
tures of aged skin associated with degraded or degenerated 
elastic properties [28], it is essential to explore strategies to 
demonstrate anti-ageing benefits.  
 The interaction of the hyaluronic acid as a component of 
the ECM and cytoskeleton constituents is known to regulate 
important phenomena such as cell division and differentia-
tion [29]. This is crucial for normal skin biology and preser-
vation of its features including mechanical properties. Hence 
the presence of HA in peptide/HA solid-in-oil nanodisper-
sion had an important effect on the density of cytoskeleton 
filaments. Cytoskeleton actin bundles encompass various 
vital cellular processes including the cytoskeleton stress fi-
bers. Actin-based cytoskeleton bundles contribute to the ac-
tively regulated nuclear positioning during mitosis [30] and 
stabilize cell shape [31]. The proportion of actin expression 
is also correlated with the contractile efficiency of individual 
fibroblasts and hence with wrinkle formation [32]. The 
higher density of actin filaments suggests a possible modula-
tion of fibroblasts cell stiffness, shape and migration which 
affect skin biology and ageing. 
 Fig. 2 presents the actin cytoskeleton comparing fibro-
blasts for both cell types (ASF-2 and BJ-5ta) for 24 hours. 
Our results point out those cells grown in the presence of HA 
exhibiting thicker actin filament bundles producing an actin 
cytoskeleton more prominent compared to controls. Pep-
tide/HA formulation in the culture medium greatly enhanced 
the aggregation of actin which forms thick filament bundles. 
The presence of free HA also contributes for a dense actin 
filament bundles. This effect was effective for both types of 
cells being more pronounced for primary human fibroblasts 
(ASF-2). This result represents a great achievement once 
actin cytoskeleton plays greater role in the interaction be-
tween the ECM and fibroblasts. The combination of peptide 
with HA promotes an improvement in the density of 
cytoskeleton bundles that could constitute a valuable data to 
protect skin against ageing effects.  
 The perfusion profile of peptide/HA S/O nanodispersion 
into the skin was assessed qualitatively and quantitatively. 
Briefly, the solid-in-oil nanodispersion was prepared as fol-
lows: the mixture of peptide/HA was coated with a lipophilic 
surfactant and then highly dispersed in oil, generating 
spherical and homogeneous structures, as shown in supple-
mentary data (Fig. S1 in Supplementary data). Storage stabil-
ity was evaluated at room temperature, and the results indi-
cated that peptide/HA solid-in-oil nanodispersion showed 
good stability over 2 months, presenting a slight aggregation 
after 3 months of storing (Fig. S2 in Supplementary data). 
No significant toxicity to the fibroblasts and keratinocytes 
was observed for formulation concentrations between 2.5 to 
10 g/mL of peptide and 0.03 to 0.12 g/mL of HA, after 
48h of incubation (Fig. S3 in Supplementary data).  
 From Fig. 3 the peptide/HA nanodispersion successfully 
permeated into the skin layers. The skin permeation was con-
firmed by molecular dynamics simulations (Fig. 4), showing 
that peptide/HA S/O nanodispersion was rapidly integrated 
into the lipids. The generated results obtained by the simula-
tions demonstrated that each component of the formulations 
have it specific importance. Peptide/HA S/O nanodispersion 
are coated with hydrophobic surfactant molecules and then 
dispersed in IPM which plays greater role in S/O nanodisper-
sion interaction with lipids. The formulation applied to the 
donor compartment, promotes high cumulative permeation 
amounts of peptide/HA through the skin (Table 1). The 
greatest permeation was observed at 48 hours indicating a 
great diffusion of the components. These results are funda-
mental to demonstrate a successful permeation of the peptide 
and hyaluronic acid spread into the skin. The overall of 
.nanodispersion methodology and the effects of each compo-
nent, peptide and HA, after an effective skin delivery is cru-
cial for their availability and biology performance (Fig. 5).  
CONCLUSION 
 A potential cosmetic application for a competitive inhibi-
tor peptide of HNE with HA was successfully established in 
this study. The formulation of the nanodispersion was fun-
damental to deliver the peptide and HA into the skin. The 
individual effect of each component, peptide that prevents or 
inhibits active MMP-1 and HA that preserves skin biology, 
showed remarkable advances for skin ageing.  
 The peptide/HA solid-in-oil nanodispersion successfully 
inhibit HNE action and therefore reduce the levels of active 
MMP-1 suggesting an indirect powerful anti-ageing benefit 
at the level of skin integrity and maintenance of elastic prop-
erties. Additionally, an enhancement in density of actin fila-
ments bundles of dermal fibroblasts was achieved due to the 
presence of HA. These results obtained for an aqueous envi-
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ronment of in vitro fibroblasts culture are reinforced by the 
good penetration profile into the deep layers of skin and dis-
sociation of the nanodispersion complex. Thus, the results 
emphasize the huge prospective of peptide/HA soli-in-oil 
nanodispersion to be applied on a pharma/cosmetic composi-
tion products, specially designed for anti-ageing applica-
tions.  
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